Study Questions “Liberal” Proton Pump Inhibitor Use
This article was originally published in The Tan Sheet
Executive Summary
A Canadian study supporting a link between proton pump inhibitors and osteoporosis-related fractures could lead to questions about OTC access to PPIs and shows a need to educate consumers regarding individual fracture risk, the authors say
You may also be interested in...
PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk
PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk
PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk